Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...

Getting ready for coding interviews can feel like a big task, and figuring out the best way to tackle LeetCode is a common question. Many people find that using Python for their LeetCode solutions ...

Recursion Pharmaceuticals stock jumped 16% on October 8, 2025, reaching around $6.08 after falling 5.4% the previous day on broader market weakness. The company reported Q2 2025 revenue of $19.2 ...

This AI company isn't yet living up to the hype. Let's discuss Recursion Pharmaceuticals' performance over the past four years and whether the company can deliver solid returns in the future. It can ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Are you ahead, or behind on retirement? SmartAsset's free ...

The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. This was largely due to news from a ...